Jevtana

Jevtana is a prescription drug used for treating prostate cancer. This chemotherapy medication works by interfering with certain cell structures, stopping the cancer cells from growing and multiplying. Jevtana, which is administered intravenously, is usually given once every three weeks and is combined with oral prednisone tablets. Possible side effects include anemia, leukopenia, and neutropenia.

Jevtana Chemotherapy Information

What Is Jevtana?

Jevtana^® (cabazitaxel) is a chemotherapy medication approved for the treatment of prostate cancer. Specifically, it is approved for use when certain other treatments have failed, and should be used in combination with prednisone.

(Click Jevtana Uses for more information on this topic, including possible off-label uses.)

Who Makes It?

Jevtana is made by sanofi-aventis U.S., LLC.

How Does Jevtana Work?

Jevtana belongs to a group of medications called taxanes. Taxanes stop cancer cells from growing and multiplying by interfering with certain structures in the cell.

Although Jevtana can kill both healthy and cancerous cells, it has a greater effect on cells that are multiplying rapidly. Generally, cancer cells multiply more rapidly than healthy cells and are, therefore, more affected by Jevtana.

Clinical Effects

One study looked at using Jevtana plus prednisone to treat metastatic prostate cancer (prostate cancer that has spread to other parts of the body) in people who had been unsuccessfully treated with certain other types of chemotherapy. People were given either Jevtana plus prednisone or mitoxantrone (Novantrone^®) plus prednisone. Compared to the mitoxantrone/prednisone combination, the Jevtana/prednisone combination increased the average survival time from 12.7 months to 15.1 months.

Jevtana Article Continues on Next Page >